Raltegravir, maraviroc, etravirine: An effective protease inhibitor and nucleoside reverse transcriptase inhibitor-sparing regimen for salvage therapy in HIV-infected patients with triple-class experience

Silvia Nozza; Laura Galli; Francesca Visco; Alessandro Soria; Filippo Canducci; Stefania Salpietro; Nicola Gianotti; Alba Bigoloni; Liviana Della Torre; Giuseppe Tambussi; Adriano Lazzarin; Antonella Castagna

doi:10.1097/QAD.0b013e3283372d76

Raltegravir, maraviroc, etravirine: An effective protease inhibitor and nucleoside reverse transcriptase inhibitor-sparing regimen for salvage therapy in HIV-infected patients with triple-class experience

Silvia Nozza, Laura Galli, Francesca Visco, Alessandro Soria, Filippo Canducci, Stefania Salpietro, Nicola Gianotti, Alba Bigoloni, Liviana Della Torre, Giuseppe Tambussi, Adriano Lazzarin, Antonella Castagna

IRCCS Ospedale San Raffaele

Research output: Contribution to journal › Article › peer-review

Abstract

We prospectively evaluated 28 triple-class experienced HIV-1-infected patients harbouring R5 virus, who received maraviroc, raltegravir and etravirine. By on-treatment analysis, 26 (92%) had less than 50 copies HIV-RNA/ml at week 48. The median (interquartile range) 48-week increase in CD4 cell counts was 267 (136-355) cells/μl. Three serious adverse events occurred: one recurrence of mycobacterial spondylodiscitis, one anal cancer, one Hodgkin lymphoma. Although long-term safety needs further study, this protease inhibitor and nucleoside analogue-sparing regimen showed sustained efficacy.

Original language	English
Pages (from-to)	924-928
Number of pages	5
Journal	AIDS (London, England)
Volume	24
Issue number	6
DOIs	https://doi.org/10.1097/QAD.0b013e3283372d76
Publication status	Published - Mar 2010

ASJC Scopus subject areas

Immunology and Allergy
Immunology
Infectious Diseases

Access to Document

10.1097/QAD.0b013e3283372d76

Fingerprint

Dive into the research topics of 'Raltegravir, maraviroc, etravirine: An effective protease inhibitor and nucleoside reverse transcriptase inhibitor-sparing regimen for salvage therapy in HIV-infected patients with triple-class experience'. Together they form a unique fingerprint.

Cite this

Nozza, S., Galli, L., Visco, F., Soria, A., Canducci, F., Salpietro, S., Gianotti, N., Bigoloni, A., Torre, L. D., Tambussi, G., Lazzarin, A., & Castagna, A. (2010). Raltegravir, maraviroc, etravirine: An effective protease inhibitor and nucleoside reverse transcriptase inhibitor-sparing regimen for salvage therapy in HIV-infected patients with triple-class experience. AIDS (London, England), 24(6), 924-928. https://doi.org/10.1097/QAD.0b013e3283372d76

Raltegravir, maraviroc, etravirine : An effective protease inhibitor and nucleoside reverse transcriptase inhibitor-sparing regimen for salvage therapy in HIV-infected patients with triple-class experience. / Nozza, Silvia ; Galli, Laura; Visco, Francesca et al.

In: AIDS (London, England), Vol. 24, No. 6, 03.2010, p. 924-928.

Research output: Contribution to journal › Article › peer-review

Nozza, S , Galli, L, Visco, F, Soria, A, Canducci, F, Salpietro, S, Gianotti, N, Bigoloni, A, Torre, LD, Tambussi, G, Lazzarin, A & Castagna, A 2010, 'Raltegravir, maraviroc, etravirine: An effective protease inhibitor and nucleoside reverse transcriptase inhibitor-sparing regimen for salvage therapy in HIV-infected patients with triple-class experience', AIDS (London, England), vol. 24, no. 6, pp. 924-928. https://doi.org/10.1097/QAD.0b013e3283372d76

@article{f6ec6a30e3ce45f0b425f3f27bbf95b7,

title = "Raltegravir, maraviroc, etravirine: An effective protease inhibitor and nucleoside reverse transcriptase inhibitor-sparing regimen for salvage therapy in HIV-infected patients with triple-class experience",

abstract = "We prospectively evaluated 28 triple-class experienced HIV-1-infected patients harbouring R5 virus, who received maraviroc, raltegravir and etravirine. By on-treatment analysis, 26 (92%) had less than 50 copies HIV-RNA/ml at week 48. The median (interquartile range) 48-week increase in CD4 cell counts was 267 (136-355) cells/μl. Three serious adverse events occurred: one recurrence of mycobacterial spondylodiscitis, one anal cancer, one Hodgkin lymphoma. Although long-term safety needs further study, this protease inhibitor and nucleoside analogue-sparing regimen showed sustained efficacy.",

author = "Silvia Nozza and Laura Galli and Francesca Visco and Alessandro Soria and Filippo Canducci and Stefania Salpietro and Nicola Gianotti and Alba Bigoloni and Torre, {Liviana Della} and Giuseppe Tambussi and Adriano Lazzarin and Antonella Castagna",

year = "2010",

month = mar,

doi = "10.1097/QAD.0b013e3283372d76",

language = "English",

volume = "24",

pages = "924--928",

journal = "AIDS",

issn = "0269-9370",

publisher = "NLM (Medline)",

number = "6",

}

TY - JOUR

T1 - Raltegravir, maraviroc, etravirine

T2 - An effective protease inhibitor and nucleoside reverse transcriptase inhibitor-sparing regimen for salvage therapy in HIV-infected patients with triple-class experience

AU - Nozza, Silvia

AU - Galli, Laura

AU - Visco, Francesca

AU - Soria, Alessandro

AU - Canducci, Filippo

AU - Salpietro, Stefania

AU - Gianotti, Nicola

AU - Bigoloni, Alba

AU - Torre, Liviana Della

AU - Tambussi, Giuseppe

AU - Lazzarin, Adriano

AU - Castagna, Antonella

PY - 2010/3

Y1 - 2010/3

N2 - We prospectively evaluated 28 triple-class experienced HIV-1-infected patients harbouring R5 virus, who received maraviroc, raltegravir and etravirine. By on-treatment analysis, 26 (92%) had less than 50 copies HIV-RNA/ml at week 48. The median (interquartile range) 48-week increase in CD4 cell counts was 267 (136-355) cells/μl. Three serious adverse events occurred: one recurrence of mycobacterial spondylodiscitis, one anal cancer, one Hodgkin lymphoma. Although long-term safety needs further study, this protease inhibitor and nucleoside analogue-sparing regimen showed sustained efficacy.

AB - We prospectively evaluated 28 triple-class experienced HIV-1-infected patients harbouring R5 virus, who received maraviroc, raltegravir and etravirine. By on-treatment analysis, 26 (92%) had less than 50 copies HIV-RNA/ml at week 48. The median (interquartile range) 48-week increase in CD4 cell counts was 267 (136-355) cells/μl. Three serious adverse events occurred: one recurrence of mycobacterial spondylodiscitis, one anal cancer, one Hodgkin lymphoma. Although long-term safety needs further study, this protease inhibitor and nucleoside analogue-sparing regimen showed sustained efficacy.

UR - http://www.scopus.com/inward/record.url?scp=77949551533&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949551533&partnerID=8YFLogxK

U2 - 10.1097/QAD.0b013e3283372d76

DO - 10.1097/QAD.0b013e3283372d76

M3 - Article

C2 - 20154578

AN - SCOPUS:77949551533

VL - 24

SP - 924

EP - 928

JO - AIDS

JF - AIDS

SN - 0269-9370

IS - 6

ER -

Raltegravir, maraviroc, etravirine: An effective protease inhibitor and nucleoside reverse transcriptase inhibitor-sparing regimen for salvage therapy in HIV-infected patients with triple-class experience

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this